glucagon is the most under-discussed thing on this board
Something I keep coming back to: glucagon is the most under-discussed thing on this board. Imaging-derived liver fat fraction is a surrogate. It correlates with histology imperfectly, and a trial reporting one is not reporting the other. Nothing containing this compound is approved anywhere. Research-use-only…
How fast was the escalation in that protocol?
glucagon agonism and energy expenditure is the mechanistic thread
Has anyone posted an independent purity result for this compound?
Asked here what the difference was between the imaging and biopsy endpoints and got a genuinely excellent answer.
glucagon agonism and energy expenditure is the mechanistic thread
This is the framing the board needs. It is a hepatic programme first.
This is the framing the board needs.
Disagreeing with this bit: that number comes from a different programme with a different population.
Disagreeing with this bit: that number comes from a different programme with a different population.
kaia_wojcik is right that biopsy and imaging endpoints are not interchangeable.
MASH endpoints are histological, which is a much harder bar
the titration in the trials was slow and deliberate